share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Dubovsky Filip

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Dubovsky Filip

諾瓦瓦克斯醫藥 | 4:持股變動聲明-高管 Dubovsky Filip
美股SEC公告 ·  06/21 05:12

Moomoo AI 已提取核心訊息

On June 17, 2024, Novavax's President of R&D, Filip Dubovsky, completed a series of transactions involving the company's common stock. Dubovsky executed the sale of 13,904 shares at prices ranging from $14.46 to $14.54 per share, resulting in a total market value of $201,164.16. Prior to the sales, Dubovsky acquired the same number of shares through the exercise of derivative securities at prices between $6.09 and $6.97. Following these transactions, Dubovsky's direct holdings in Novavax common stock amounted to 66,613 shares.
On June 17, 2024, Novavax's President of R&D, Filip Dubovsky, completed a series of transactions involving the company's common stock. Dubovsky executed the sale of 13,904 shares at prices ranging from $14.46 to $14.54 per share, resulting in a total market value of $201,164.16. Prior to the sales, Dubovsky acquired the same number of shares through the exercise of derivative securities at prices between $6.09 and $6.97. Following these transactions, Dubovsky's direct holdings in Novavax common stock amounted to 66,613 shares.
2024年6月17日,諾瓦瓦克斯醫藥的研發總裁Filip Dubovsky完成了一系列涉及該公司普通股的交易。Dubovsky以每股14.46美元至14.54美元的價格出售了13,904股,總市值爲201,164.16美元。在進行銷售之前,Dubovsky以6.09美元至6.97美元的價格通過衍生證券行權獲取了相同數量的股份。在這些交易後,Dubovsky在諾瓦瓦克斯醫藥的普通股中的直接持股總數爲66,613股。
2024年6月17日,諾瓦瓦克斯醫藥的研發總裁Filip Dubovsky完成了一系列涉及該公司普通股的交易。Dubovsky以每股14.46美元至14.54美元的價格出售了13,904股,總市值爲201,164.16美元。在進行銷售之前,Dubovsky以6.09美元至6.97美元的價格通過衍生證券行權獲取了相同數量的股份。在這些交易後,Dubovsky在諾瓦瓦克斯醫藥的普通股中的直接持股總數爲66,613股。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息